TheraRadar
← Back
Data updated: Mar 29, 2026

ACS DOBFAR

Infectious DiseaseDermatology
Generics

ACS DOBFAR is a generic drug manufacturer focused on Infectious Disease, Dermatology.

1973
Since
10
Drugs
-
Trials
49
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

MEROPENEM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
AMPICILLIN AND SULBACTAM 2026-02-17
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 60%
3 drugs
Dermatology 40%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology
COSETTE other
Dermatology, Infectious Disease
BAUSCH AND LOMB specialty
Infectious Disease, Dermatology